The announcement is a low-impact pipeline update with no near-term revenue or clinical catalysts. Monitor for any future clinical trial results or expansion of the distribution agreement, but no immediate trading action warranted.
Price Chart
Executive Summary
EUDA Health announced that its partner Shenzhen Inno Immune received government approval for a TCR-T cell therapy R&D project under the Shenzhen Key Industry R&D Program, with potential funding of up to ~$435K. EUDA holds non-exclusive distribution rights for selected immunotherapies in Malaysia. The announcement is a minor positive for EUDA's pipeline exposure but lacks near-term revenue or clinical milestone impact.
Key Financial Metrics
Key Facts
- Shenzhen Inno Immune received approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T therapy project targeting solid tumors.
- Potential government funding of up to ~US$434,688 for the project, running from Jan 1, 2026 to Dec 31, 2028.
- EUDA holds non-exclusive distribution rights to market and sell Shenzhen Inno's selected immunotherapies in Malaysia via subsidiary CK Health Plus Sdn Bhd.
- The project focuses on AI-driven antigen screening and TCR-T engineering to address T-cell exhaustion and persistence in solid tumors.
- No financial terms of the distribution agreement or near-term revenue expectations were disclosed.
Financial Impact
Up to ~$435K in potential government funding to partner; no direct revenue impact disclosed for EUDA.
Risk Factors
- TCR-T therapy is early-stage with high clinical and regulatory risk; no guarantee of commercial success.
- EUDA's distribution rights are non-exclusive and limited to Malaysia, limiting revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $17.01 $14.90 | ▲ +12.40% | ▲ +11.25% | $14.65 (+13.87%) |
Oct 13, 2026 14d ago | 6-K | $17.01 $14.90 | ▼ −12.40% | ▼ −11.25% | $14.65 (−13.87%) |
Aug 26, 2026 8w ago | Press Release | $14.10 $13.84 | ▼ −1.84% | ▼ −1.72% | $14.65 (+3.90%) |
Aug 11, 2026 11w ago | EFFECT | $15.23 $14.49 | ▲ +4.87% | ▲ +4.47% | $14.65 (+3.81%) |
Jul 31, 2026 12w ago | 6-K | $19.30 $15.90 | ▼ −17.62% | ▼ −21.13% | $14.65 (−24.09%) |
Jul 22, 2026 13w ago | 424B5 | $14.00 $20.35 | ▲ +45.36% | ▲ +47.76% | $14.65 (+4.64%) |
Jun 11, 2026 19w ago | 424B5 | $15.02 $16.49 | ▲ +9.79% | ▲ +9.35% | $14.65 (−2.46%) |
Apr 28, 2026 26w ago | Press Release | $12.00 $16.31 | ▲ +35.92% | ▲ +34.22% | $14.65 (+22.08%) |
Mar 19, 2026 31w ago | Press Release | $7.98 $11.44 | ▲ +43.36% | ▲ +45.57% | $14.65 (+83.58%) |
Mar 4, 2026 33w ago | Press Release | $15.74 $10.04 | ▼ −36.21% | ▼ −34.88% | $14.65 (−6.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers